Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02979938
Other study ID # ZIKAFERTI
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2016
Est. completion date August 2017

Study information

Verified date May 2018
Source Trinidad and Tobago IVF and Fertility Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.


Description:

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.

Knowledge of the possible presence, infectivity and persistence of ZIKV in semen will provide evidence-based data for

1. estimating of the risk of sexual transmission of ZIKV in the general population

2. antenatal guidelines for the prevention of sexual transmission of ZIKV to the fetus

3. advising couples on the length of time that pregnancy should be avoided in women wishing to conceive after their partner's ZIKV infection

4. strategies to prevent transmission of ZIKV infection through assisted reproductive treatment (ART)

5. advice on gamete cryopreservation

6. optimising investigations for diagnosis of ZIKV in males.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Male aged 18-50 years

- ZIKV symptoms within the preceding thirty days

- Confirmed ZIKV infection (WHO criteria)

- Able to ejaculate to produce a semen sample

Exclusion Criteria:

• Current urological malignancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Semen analysis and semen PCR for Zika virus
Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.

Locations

Country Name City State
Trinidad and Tobago Trinidad and Tobago IVF & Fertility Centre Maraval

Sponsors (2)

Lead Sponsor Collaborator
Trinidad and Tobago IVF and Fertility Centre Institute of Tropical Medicine, Belgium

Country where clinical trial is conducted

Trinidad and Tobago, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of the presence (with RT-PCR) of ZIKV in semen 6 months
Secondary Measurement of the viral load (with ct values) of ZIKV in semen 6 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04182685 - Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
Enrolling by invitation NCT04398901 - Neurodevelopmental Outcomes in ZIKV-Exposed Children
Completed NCT02996890 - Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) Phase 1
Completed NCT03188731 - ZIKAlliance Pregnant Women Cohort
Completed NCT03110770 - VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Phase 2
Active, not recruiting NCT04917861 - A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas Phase 2
Completed NCT02794181 - Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT03611946 - Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Phase 1
Completed NCT04064905 - Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Phase 1
Completed NCT03106714 - Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
Recruiting NCT03227601 - Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome N/A
Completed NCT03393286 - ZIKAlliance Children Cohort (ZIKAllianceCH)
Completed NCT03425149 - Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults Phase 1
Recruiting NCT05123222 - Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) Phase 1
Completed NCT02733796 - Persistence of Zika Virus in Semen After Acute Infection
Completed NCT03014089 - Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects Phase 1
Completed NCT03263195 - Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
Withdrawn NCT03204409 - ZIKAlliance Natural History Study